A randomized, phase IIb study of adjuvant durvalumab (MEDI4736) plus regorafenib vs untreated control in stage IV colorectal cancer patients with no evidence of disease (NED): VIVA trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518217-26-00

Acronym

VIVA

Enrollment

182

Registered

2024-10-28

Start date

2021-10-20

Completion date

Unknown

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IV colorectal cancer patients with no evidence of disease (NED)

Brief summary

Disease-Free Survival (DFS)

Detailed description

● 18-months Disease-Free Survival (DFS), ● Adverse events and Toxicity, ● Overall Survival (OS), ● Compliance to the experimental treatment

Interventions

DRUGBAY 734506

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
● 18-months Disease-Free Survival (DFS), ● Adverse events and Toxicity, ● Overall Survival (OS), ● Compliance to the experimental treatment	—

Primary

Measure	Time frame
Disease-Free Survival (DFS)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026